Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an important issueRobin Arcani, Gilles Kaplanski, Julien Colle et al.|Annals of Hematology|2021Cited by 22
High incidence of CDA deficiency in patients with hematological malignancies: perspectives and therapeutic implicationsMélanie Donnette, Raphaëlle Fanciullino, Christel Pissier et al.|Annals of Oncology|2021Cited by 8
Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative NeoplasmNorman Abbou, Geoffroy Venton, Pauline Piazzola et al.|Cells|2022Cited by 5
Could daratumumab induce the maturation of plasmablasts in Plasmablastic lymphoma?—Potential therapeutic applicationsPauline Roché, Laure Farnault, Geoffroy Venton et al.|European Journal Of Haematology|2021Cited by 4
Therapy-related myeloid neoplasms after 177Lu-DOTATATE therapy for metastatic neuroendocrine neoplasia: CPX-351 consolidated by allogeneic stem cells transplantation as applicable therapeutic strategyGuillaume Berton, Geoffroy Venton, Robin Arcani et al.|Leukemia & lymphoma/Leukemia and lymphoma|2023Cited by 0